400

3-({[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]CARBONYL}AMINO)-N-[(1R)-1-PHENYLPROPYL]-1H-THIENO[3,2-C]PYRAZOLE-5-CARBOXAMIDE

Created:	2009-09-03
Last modified:	2021-03-01

Find Related PDB Entry
1 entries where 400 is found as a standalone ligand

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	66
Chiral Atom Count	1
Bond Count	70
Aromatic Bond Count	21

2D diagram of 400

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	3-({[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]CARBONYL}AMINO)-N-[(1R)-1-PHENYLPROPYL]-1H-THIENO[3,2-C]PYRAZOLE-5-CARBOXAMIDE
Synonyms	PHA-828300
Systematic Name (OpenEye OEToolkits)	3-[[4-(4-methylpiperazin-1-yl)phenyl]carbonylamino]-N-[(1R)-1-phenylpropyl]-1H-thieno[5,4-d]pyrazole-5-carboxamide
Formula	C₂₇ H₃₀ N₆ O₂ S
Molecular Weight	502.631
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	10.04	O=C(c1sc4c(c1)nnc4NC(=O)c3ccc(N2CCN(C)CC2)cc3)NC(c5ccccc5)CC
SMILES	CACTVS	3.352	CC[CH](NC(=O)c1sc2c([nH]nc2NC(=O)c3ccc(cc3)N4CCN(C)CC4)c1)c5ccccc5
SMILES	OpenEye OEToolkits	1.6.1	CCC(c1ccccc1)NC(=O)c2cc3c(s2)c(n[nH]3)NC(=O)c4ccc(cc4)N5CCN(CC5)C
Canonical SMILES	CACTVS	3.352	CC[C@@H](NC(=O)c1sc2c([nH]nc2NC(=O)c3ccc(cc3)N4CCN(C)CC4)c1)c5ccccc5
Canonical SMILES	OpenEye OEToolkits	1.6.1	CC[C@H](c1ccccc1)NC(=O)c2cc3c(s2)c(n[nH]3)NC(=O)c4ccc(cc4)N5CCN(CC5)C
InChI	InChI	1.03	InChI=1S/C27H30N6O2S/c1-3-21(18-7-5-4-6-8-18)28-27(35)23-17-22-24(36-23)25(31-30-22)29-26(34)19-9-11-20(12-10-19)33-15-13-32(2)14-16-33/h4-12,17,21H,3,13-16H2,1-2H3,(H,28,35)(H2,29,30,31,34)/t21-/m1/s1
InChIKey	InChI	1.03	BGKRQXRINOKEMF-OAQYLSRUSA-N

Related Resource References

Resource Name	Reference
Pharos	CHEMBL1230201
PubChem	11846878
ChEMBL	CHEMBL1230201

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.